Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report), Cidara Therapeutics (CDTX – Research Report) and Gamida Cell (GMDA – Research Report). Qiagen (QGEN) UBS analyst John Sourbeer maintained a Hold rating on Qiagen yesterday. The company's shares closed last Tuesday at $44.91. According to TipRanks.com, Sourbeer is ranked #7410 out of 7890 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $53.20 average price target. See Insiders’ Hot Stocks on TipRanks >> Cidara Therapeutics (CDTX) In a report released yesterday, Ed Arce from H.C.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-cidara-therapeutics-cdtx-and-gamida-cell-gmda?utm_source=advfn.com&utm_medium=referral
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Qiagen NV Charts.
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Qiagen NV Charts.